Drug intelligence / Profile preview

HPG-3466

Development stage: Preclinical
Lead developer: Hepagene Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

HPG-3466 is a small molecule drug developed by Hepagene Therapeutics. It acts as a highly effective and specific antagonist of the inhibitors of apoptosis (IAP) protein family. By inhibiting IAP proteins, HPG-3466 promotes apoptosis in target cells, which is relevant for its potential use in cancer therapy and other diseases where evasion of cell death is a factor. The drug has demonstrated efficacy in preclinical models and holds global intellectual property rights under Hepagene Therapeutics. Its primary indications under investigation are solid tumors (neoplasms) and hepatitis B[1][4].

Targets

IAP (Inhibitor of apoptosis protein family)

Beyond the preview

Go deeper on HPG-3466.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HPG-3466.

Explore the full profile